This group of clonal mutations are enriched in HR-MDS patients and is predicted with limited impact on AML transformation in comparison with “type 1 mutations”, including FLT3, RAS, and IDH1/2, which harbor a significant impact on patient survival and AML progression. The gene discussed is FLT3; the disease is acute myeloid leukemia.